Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million

Pentixapharm Holding AG / Key word(s): Preliminary Results

Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million

24-Jan-2025 / 17:00 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Berlin, January 24, 2025 – According to initial preliminary evaluations, Pentixapharm Holding AG will close the 2024 financial year with a loss of around EUR 14 million. In addition to the operating loss of EUR 7 million, the total also includes non-cash write-downs for intangible assets. They result from the termination of development projects at the subsidiary Myelo Therapeutics GmbH, which were previously mainly financed by contracts from various US government agencies. According to the opinion of the Management Board and Supervisory Board, the recent change in the U.S. administration has significantly worsened the conditions for amortization, as previous funding programs have been canceled or not extended.

The annual report for 2024 with details of the development project will be published on April 15, 2025.

For more information, please contact:

Pentixapharm Holding AG
Phillip Eckert, Investor Relations
ir@pentixapharm.com
Tel. +49 30 94893232
www.pentixapharm.com

End of Inside Information


Information and Explanation of the Issuer to this announcement:

About Pentixapharm

Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds as well as early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.


24-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Significant progress in all operating areas; stable fourth quarter leads to annual sales of EUR 12.2 million (+6%)

EQS-News: aap Implantate AG

/ Key word(s): Sales Result

Significant progress in all operating areas; stable fourth quarter leads to annual sales of EUR 12.2 million (+6%)

24.01.2025 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

aap Implantate AG (“aap” or “Company”) informs that with the end of a stable fourth quarter a preliminary sales growth of 6.3% compared to the previous year could be achieved. Growth was achieved in all regions except the USA. The investment in further aap systems to equip customers characterized the product mix, so that the company sees a good basis for further growth. In the USA, sales decreased due to the restructuring carried out in the fourth quarter of 2023 (minus 19% for the year as a whole) and recovered in the last quarter of 2024 to -11% compared to the same quarter of the previous year.

Turnover FY/2024

in TEUR FY/2024 FY/2023 Change
Trauma
 EMEA (=Europe, Middle East, Africa)
North America (=USA)
LATAM (= Latin America)
APAC (=Asia-Pacific)
 
6.329
2.874
2.534
   466
 
   5.475
   3.567
   2.083
      352
 
16%
-19%
22%
32%
Turnover 12,203 11.477 6%

 

aap made significant progress in 2024:

  • Due to the very good progress of the study with the antibacterial surface-treated implants, patient recruitment was completed ahead of schedule after consultation with the BfArM and the Ethics Committee;
  • The successful completion of the first MDR audit in September and the positive MDR assessment of the first product file pave the way for a foreseeable conclusion to the MDR certification process;
  • Approvals in new markets, primarily in the APAC region, provide a good basis for future growth;
  • Equity was significantly strengthened through various capital measures
  • the operating cash flow was improved by the 2023 restructuring, among other things

The company will provide information on the outlook for the 2025 financial year and the management agenda in a separate announcement.

The sales figures contained in this press release are preliminary figures as of December 31, 2024, which are subject to change until final publication. aap plans to announce the final, audited results for the financial year 2024 at the end of April as part of the consolidated annual financial report 2024.

 

 

——————————————————————————————————————————————-

aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German stock exchanges –

 

 

About aap Implantate AG

aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. The IP-protected portfolio includes the innovative anatomical plate system LOQTEQ® and a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while internationally it primarily uses a broad network of distributors in around 25 countries. In the United States, the company and its subsidiary aap Implants Inc. rely on a sales strategy via distribution agents and selective direct sales. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.

 

The figures presented in this press release may be subject to technical rounding differences that do not affect the overall picture.

 

Forward-looking statements

This release may contain forward-looking statements that are based on the current expectations, assumptions and forecasts of the Executive Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situation, development or performance of the company and the estimates given here. These factors include those that aap has described in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.

 

If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo; Chairman of the Management Board/ CEO; Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 – 141; Fax: +49 (0)30 75019 – 290; Email: r.digirolamo@aap.de


24.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

EQS-News: ABIVAX

/ Key word(s): Study results

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

23.01.2025 / 22:05 CET/CEST

The issuer is solely responsible for the content of this announcement.

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress 

PARIS, France – January 23, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod, [an investigational, orally administered, once-daily small molecule] in clinical development for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at The European Crohn’s and Colitis Organization’s (ECCO’s) 20th Annual Congress as part of scientific exchange, taking place February 19-22, 2025, in Berlin, Germany.

“With 7 abstracts accepted for presentation at ECCO 2025, we look forward to our continued exchange with the inflammatory bowel disease community around the emerging clinical profile of obefazimod,” said Fabio Cataldi, MD, Chief Medical Officer of Abivax

For more information, see congress details on the ECCO website, and visit the Abivax booth at the ECCO exhibitor hall (booth #30).

Obefazimod data to be presented:

Presentation Title Session Presenter Presentation/ Session Number Session Hall Date and Time (EDT)
Oral Presentation
“Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QD”
 
Digital Oral Presentation Session 6
 
Prof. Silvio Danese, MD, PhD
 
Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital

 

 Clinical Trials III
 
Hall A7
 
Friday, February 21, 2025
 
8:42am to 8:48am
 
Poster Presentations
“Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study”
 
Guided Poster Session
 
Fernando Magro, MD, PhD
 
President-Elect of ECCO. Head of the Department of Clinical Pharmacology and Professor of Pharmacology and Therapeutics at University Hospital São João in Porto, Portugal
 
 Poster number: P0636
 
 Hall 2.2
 
Friday, February 21, 2025
 
12:40pm to 1:40pm
 
“Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis”
 
Guided Poster Session
 
Prof. Séverine Vermeire, MD, PhD
 
Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC
 
 Poster number: P0813
 
 Hall 2.2
 
Friday, February 21, 2025

12:40pm to 1:40pm
 

“Health-related quality of life (HRQOL) in patients with ulcerative colitis (UC) treated with obefazimod: the phase 2 open-label maintenance study”
 
Guided Poster Session
 
Jennifer Fine, ScD
Head of HEOR, Abivax S. A
 
 Poster number: P0840
 
 Hall 2.2
 
Friday, February 21, 2025
 
12:40pm to 1:40pm
 
“Efficacy and safety of obefazimod for the fourth and sixth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): 2-year interim analysis after dose de-escalation to 25 mg”
 
Guided Poster Session
 
Prof. Silvio Danese, MD, PhD
 
Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital
 
  Hall 2.2
 
Friday, February 21, 2025
 
12:40pm to 1:40pm
 
“Long-term treatment patterns, dose escalation, and steroid use among patients with moderate-to-severe ulcerative colitis using advanced therapies: 3 years of continuous follow-up using IQVIA PharMetrics Plus database”
 
Guided Poster Session
 
Prof. Parambir S. Dulai, M.D.
 
Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois
 
  Hall 2.2
 
Friday, February 21, 2025
 
12:40pm to 1:40pm
 
“Synergistic reduction of inflammatory cytokines with obefazimod and etrasimod in combination treatment vs. either monotherapy in a mouse model of inflammatory bowel disease” Guided Poster Session Didier Scherrer, PhD
Chief Scientific Officer
Abivax S.A.
  Hall 2.2 Friday, February 21, 2025
 
12:40pm to 1:40pm

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878


23.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors

Galenica AG

/ Key word(s): Personnel

Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors

23.01.2025 / 07:00 CET/CEST

Press release

Nadine Balkanyi-Nordmann, an experienced legal, compliance and governance expert, will be recommended for election as a member of the Board of Directors at the next Annual General Meeting of the Galenica Group.

At the upcoming Annual General Meeting on 10 April 2025, a new member will be proposed to shareholders for election to the Galenica Board of Directors: Nadine Balkanyi-Nordmann (born in 1972), a recognised leader and expert in various fields of law. This would restore the Board of Directors to seven members.

 

Chairman of the Galenica Board of Directors Markus Neuhaus comments on the nomination: “I am pleased to propose Nadine Balkanyi-Nordmann for election as a new member on behalf of the entire Board of Directors. She is a respected expert in Switzerland in the field of administrative law and risk management and has extensive knowledge of conducting administrative investigations in the public sector, implementing new regulations and developing compliance programmes. In addition, she is a distinguished lawyer and has in-depth knowledge of the healthcare sector.”

 

Leading expert in financial services and healthcare

Nadine Balkanyi-Nordmann is the founder and CEO of Lexperience AG. She has worked for prominent law firms and major financial institutions and has trained at several international institutions. Following her time practising law at Walder Wyss & Partners in Zurich, the Swiss attorney held management positions for various banks such as UBS, GE Capital Bank and BNP Paribas in Asia, America and Switzerland.

 

Nadine Balkanyi-Nordmann studied law at the University of Zurich and was admitted to the Zurich bar. She also holds an LL.M. (Master of Laws) from Hong Kong University. She has extensive knowledge of corporate governance and conducting administrative investigations in the public sector. She is to reinforce the Board of Directors of the Galenica Group with her expertise in integrating ESG criteria when it comes to listed companies and implementing new regulatory requirements.

 

Nadine Balkanyi-Nordmann will not stand for re-election to the Board of Directors of Sanitas in 2025, a position she has held since 2013.

 

Photo of Nadine Balkanyi-Nordmann

Dates for the diary

11 March 2025

Publication of Annual Results of the Galenica Group 2024

10 April 2025

Annual General Meeting of Galenica Ltd.

22 May 2025 Galenica Group sales update

7 August 2025

Publication of Galenica Group half-year results 2025

 

For further information, please contact:

 

Media Relations:
Tel. +41 58 852 85 17
E-Mail:
media@galenica.com
 

Welcome to the Galenica network!
Over 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally. 

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com.


End of Media Release


show this

Galenica reports strong sales growth once again

Galenica AG / Key word(s): Development of Sales

23-Jan-2025 / 06:45 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Press release
Ad hoc announcement pursuant to Art. 53 LR

Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).

Following a solid increase in sales of 2.6% in the first half of 2024, Galenica again posted significantly stronger growth of +6.7% in the second half of 2024. Market share gains in the wholesale business with doctors and pharmacies contributed significantly to the increase in sales. In addition to acquisitions, the main growth driver in the pharmacy business was strong organic growth in sales of prescription-only medications. In addition, the second half of the year had two more sales days than in the prior-year period, which boosted growth in this half-year period by an estimated +1.6%. Due to the leap year, 2024 as a whole had one more sales day than in the previous year, which corresponds to an additional growth effect of around +0.4%.

 

By contrast, a mild flu outbreak and a low occurrence of colds in the fourth quarter of 2024 weakened sales growth, particularly in the “Products & Brands” sector. Significant additional sales of generics and biosimilars also continued to dampen growth. The generics substitution rate of Galenica pharmacies increased by 4.0% on average in 2024 to a high 79.2% (75.2% at the end of December 2023).

 

Guidance for 2024 annual results confirmed

Galenica confirms its guidance for the 2024 annual results projecting EBIT1 growth between 8% and 11% and a dividend at least at the previous year’s level.

 

Net sales of the Galenica Group January – December 2024

 

(in million CHF)

2024

2023

Change

Products & Care segment

 1,700.2

 1,635.6

3.9%

Retail (B2C)

 1,442.0

 1,385.6

4.1%

Local Pharmacies

 1,365.1

 1,306.9

4.4%

Pharmacies at Home

 77.3

 78.9

-2.1%

Professionals (B2B)

 268.2

 256.1

4.7%

Products & Brands

 183.4

 177.1

3.5%

Services for Professionals

 84.8

 78.9

7.5%

Logistics & IT segment

 3,240.7

 3,077.0

5.3%

Wholesale

 3,104.5

 2,952.7

5.1%

Logistics & IT Services

 157.2

 144.0

9.2%

Corporate and eliminations

 -1,019.2

 -966.6

 

Galenica Group

 3,921.7

 3,746.0

4.7%

 

1 Excluding the effects of IFRS 16 and IAS 19

 

PRODUCTS & CARE SEGMENT

 

The “Products & Care” segment achieved net sales of CHF 1,700.2 million (+3.9%) in the 2024 financial year. Of this, CHF 1,442.0 million (+4.1%) was attributable to “Retail” (B2C), with “Local Pharmacies” contributing CHF 1,365.1 million (+4.4%, excluding Coop Vitality) and “Pharmacies at Home” accounting for CHF 77.3 million (-2.1%, excluding Mediservice).

 

“Professionals” (B2B) increased sales to CHF 268.2 million (+4.7%), with “Products & Brands” contributing CHF 183.4 million (+3.5%) and “Services for Professionals” CHF 84.8 million (+7.5%).

 

Retail (B2C)

  • The pharmacy network (excluding Coop Vitality Coop) continued to evolve dynamically: Twelve pharmacies were acquired, two new pharmacies were opened and four were closed or merged with other locations. The expansion effect on sales growth in “Local Pharmacies” therefore amounted to +1.7%.
  • Adjusted for this expansion effect, Galenica pharmacies grew organically by 2.7% thanks to high demand for prescription-only medications.
  • Compared to the previous year, demand for vaccinations in Galenica pharmacies increased by 20% (excluding COVID-19 vaccinations).
  • Around 193,000 customers made use of the healthcare services and advice offered by Galenica pharmacies in 2024, 39% more than in the previous year.
  • The “Pharmacies at Home” sector experienced a slight decline due to the streamlining of various services. The largest business, “Bichsel HomeCare”, continued to grow steadily.

By way of comparison

  • Sales of medications from bricks-and-mortar pharmacies in Switzerland (prescription-only [Rx] and OTC products) grew by 3.5% in the reporting period (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
  • Sales of medications from mail-order pharmacies in Switzerland (prescription-only [Rx] and OTC products) declined year-on-year by -2.9% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
  • The non-drugs segment of the Consumer Healthcare market also contracted by -0.8% in the period under review (IQVIA, Consumer Health Market Switzerland, YTD December 2024, nutrition, personal care, patient care, excluding OTC).

Professionals (B2B)

  • Verfora continued to grow in 2024 and expanded its market position. Organic growth in “Products & Brands”, excluding the expansion effect (+0.7%) attributable to the acquisition of Padma in 2023, amounted to 2.8%.
  • Verfora’s export business showed very positive organic growth, with an increase of 15.1%. This pleasing result was driven by higher demand for Verfora products such as Perskindol® in Asia, and earlier product deliveries abroad compared to the previous year.
  • Due to a reduction in inventories in the market combined with a mild flu outbreak in the fourth quarter of 2024, Verfora’s Swiss business saw a slight organic decline of -0.2%. At 4.2%, sales of Verfora products in the pharmacy and drugstore market grew faster than the overall market (IQVIA, Consumer Health Market Switzerland, YTD December 2024), enabling further market share to be gained.
  • The growth drivers in “Services for Professionals” (+7.5%) were once again Lifestage Solutions, and Medifilm in the business with care homes and home care organisations.

By way of comparison

  • The consumer healthcare market grew by 1.1% year-on-year (IQVIA, Consumer Health Market Switzerland, YTD December 2024).
     

LOGISTICS & IT SEGMENT

 

The “Logistics & IT” segment achieved net sales of CHF 3,240.7 million (+5.3%) in the 2024 financial year.
Of this, CHF 3,104.5 million (+5.1%) was attributable to “Wholesale” and CHF 157.2 million (+9.2%) to “Logistics &
IT Services”.

 

Highlights

  • The pharmacy customer segment grew by 4.0%, outperforming the market.
  • At 7.8%, the greatest growth was achieved in the physicians segment, which enabled market share to be gained.
  • HCI Solutions also performed well. By the end of December, around 369 million CDS checks had been carried out (+33%), an important contribution to patient safety.

 

By way of comparison

  • The overall pharmaceutical market grew by 3.5% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
  • The physicians segment grew by 5.7% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
  • The pharmacy segment grew by 2.9% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).

 

Additional information on sales figures and further information can be found in our sales presentation.

 

Upcoming dates

11 March 2025

Publication of Annual Results 2024 of the Galenica Group

10 April 2025

Annual General Meeting of Galenica Ltd.

22 May 2025

Galenica Group sales update

7 August 2025

Publication of Galenica Group half-year results 2025

 

For further information, please contact:

 

Media Relations:
Iris Müller, Chief Communications Officer
Tel. +41 58 852 85 17
E-Mail:
media@galenica.com
Investor Relations:
Julian Fiessinger, CFO
Tel. +41 58 852 85 31
E-Mail:
investors@galenica.com

Welcome to the Galenica network!
Over 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally. 

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at www.galenica.com.


End of Inside Information


show this

Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014: Purchase of own shares – final notice

EQS-News: Drägerwerk AG & Co. KGaA

/ Key word(s): Miscellaneous

Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014: Purchase of own shares – final notice

22.01.2025 / 14:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014: Purchase of own shares – final notice

The share buyback of Drägerwerk AG & Co. KGaA (“Dräger”), which had begun on October 7, 2024, was completed on January 20, 2025. A total of 77,316 preferred shares were bought back during this period. The start of the buyback was announced on October 1, 2024. On November 22, 2024, Dräger announced the extension of the buyback.

The acquisition of the preferred shares served the purpose of fulfilling obligations relating to an employee stock program within the meaning of article 5, paragraph 2 (c) of the Regulation (EU) No 596/2014. The Executive Board did not participate in the program due to the new regulations on share-based remuneration.

A bank mandated by Dräger conducted the buyback of the Dräger preference shares exclusively on a stock exchange.

In accordance with Art. 5 (1) and (3) of the Regulation (EU) No 596/2014 and Art. 2 (2) and (3) of the Delegated Regulation (EU) 2016/1052, information about the transactions is available on the Company’s website (www.draeger.com) in the Investor Relations section (www.draeger.com/en_corp/Investor-Relations/Share).

Lübeck, Germany, January 22, 2025

Executive Board
Drägerwerk Verwaltungs AG, acting as the general partner of
Drägerwerk AG & Co. KGaA

Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com


22.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases

EQS-News: Evotec SE

/ Key word(s): Miscellaneous

Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases

22.01.2025 / 07:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

 
  • Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy
  • Funding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis
 

Hamburg, Germany, 22 January 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class to treat diseases with a high unmet medical need.

“We are excited to work together with Prof. Sunghoon Kim and our colleagues at Zymedi and Yonsei University to cooperatively advance a particularly promising approach to develop novel antibody-based treatments for asthma and IPF,” said Dr Thomas Hanke, EVP & Head of Academic Partnerships at Evotec. “The synergies between the three parties supported by the KIAT grant showcase how international collaborations can help accelerate the development of novel therapies for diseases with a high unmet medical need: Dr. Kim’s laboratory at Yonsei University has been recognized as a global leader in the field of tRNA synthetases by uncovering their diverse regulatory activities for body homeostasis. Zymedi is an aspiring Korean company translating the pathologic association of tRNA synthetases to new medicine. Evotec will bring to bear its world-class antibody development, engineering and manufacturing technologies together with its integrated preclinical R&D platforms for drug discovery and development of fibrosis and lung diseases. We are grateful to the Korean government and honored to be part of this outstanding consortium”

“The previously untapped biology of tRNA synthetases provides a versatile route for new drug development. I am very excited to launch the project with Evotec to develop novel therapeutic antibodies targeting a disease-causing activities by these enzymes” said Sunghoon Kim, Professor and Director, Institute of Artificial Intelligence and Biomedical Research at Yonsei University.

The project aims to advance first-in-class antibodies targeting a novel mechanism-of-action in the area of tRNA synthetase biology to treat IPF and non-type 2 asthma. Both disease entities are characterized by a high need to develop novel therapies that will improve future standard-of-care. 

About Yonsei University
Yonsei University, founded in 1885 in Seoul, South Korea, is a prestigious private institution renowned for academic excellence. Ranking #56 in the QS World University Rankings 2025, the university serves approximately 38,725 students across 14 colleges and 15 graduate schools, offering diverse programs in humanities, sciences, engineering, and medicine. Located primarily in Sinchon, Seoul, Yonsei’s mission focuses on educating global leaders committed to humanity’s progress. The university distinguishes itself through extensive research capabilities, 153 research centers, and a strong international perspective. With a rich academic heritage, Yonsei has produced notable alumni including a Nobel laureate and an Academy Award winner. Embodying values of “truth and freedom”, the institution continues to be a leading educational platform preparing students to become innovative global professionals. For additional information please go to www.yonsei.ac.kr.

About Zymedi
Zymedi is a clinical stage biopharmaceutical company pioneering novel biology of aminoacyl-tRNA synthetases (ARSs) as innovative therapeutic solutions. While traditionally known for their role in protein synthesis, ARSs also play crucial roles in the body’s homeostasis—an overlooked function with profound implications for human diseases. Since 2019, Zymedi has focused on harnessing the untapped potential of ARSs, developing first-in-class therapies to address critical unmet medical needs. The company’s proprietary drug discovery platform drives its innovation, enabling a robust pipeline of therapies grounded in deep ARS biology. A current key focus disease area includes immune and fibrotic diseases and cancer. Zymedi is currently collaborating with US National Heart, Lung and Blood Institute for clinical studies of ZMA001, a therapeutic antibody for pulmonary arterial hypertension. The company is located in Incheon, Korea and venture-backed. For additional information, please visit www.zymedi.com and follow us on Instagram @zymedi_official and LinkedIn. 

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 

 

For further information, please contact:

Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com 

Media
Susanne Kreuter 
VP Head of Strategic Marketing 
Susanne.Kreuter@evotec.com  


22.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

Relief Therapeutics Holding SA / Key word(s): Miscellaneous

22-Jan-2025 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE® Rights ex-US
Sale of GOLIKE® Rights Outside the U.S. to Nutrisens
Relief to Focus on R&D of Pipeline Assets and Licensing for Commercialized Products

GENEVA (JAN. 22, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTFRLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the sale of its intellectual property and commercialization rights for GOLIKE outside the United States to Nutrisens, a leading independent platform that develops and commercializes clinical nutrition solutions for patients. This transaction completes Relief’s previously announced transition from a direct marketing and sales infrastructure to a partnership-based model, enabling the Company to optimize its cost structure and allocate resources on advancing its high-priority R&D programs.

Under the agreement, Nutrisens will take over marketing and sales activities for GOLIKE in Relief’s European markets. Relief has also transferred its existing third-party distribution agreements for GOLIKE in other regions to Nutrisens, while retaining its rights in the United States, where the product is exclusively licensed to Eton Pharmaceuticals. With its significant experience, Nutrisens will continue to support patients and health professionals with GOLIKE solutions worldwide outside the United States. Relief intends to continue to supply GOLIKE globally and complete development of certain line extensions to address patient needs.

“Throughout the past year, we have progressively transformed our organization to build on our strengths in drug development and the business-to-business commercialization of our products,” said Dr. Raghuram Selvaraju, chairman of Relief’s board of directors. “This strategic transformation has refocused our efforts on developing innovative treatments, streamlined operations, and enhanced our ability to serve patients. We are well-positioned to continue advancing our programs in rare dermatology and metabolic disorders, while in parallel, we continue to explore a potential pipeline expansion into the gastrointestinal therapeutic space through our ongoing discussions with Renexxion.”

Relief received CHF 1.2 million upfront from Nutrisens and is eligible for certain contingent payments. Following this payment, Relief reported a cash balance of CHF 15.3 million as of January 22, 2025, ensuring its capacity to achieve key near-term R&D milestones and advance its strategic objectives.

ABOUT GOLIKE®
GOLIKE products are Foods for Special Medical Purposes (FSMPs) developed by Relief with prolonged-release formulations that closely replicate the physiological absorption of amino acids found in natural proteins. By masking the unpleasant taste and odor typically associated with amino acids, GOLIKE offers a more palatable and patient-friendly solution addressing key challenges in dietary management. The GOLIKE product line includes PKU GOLIKE, designed for the dietary management of phenylketonuria, as well as additional products currently in development.

ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief’s portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.

CONTACT:
RELIEF THERAPEUTICS Holding SA

Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Additional features:

File: Ad hoc


End of Inside Information


show this

SKAN announces preliminary key figures for the 2024 financial year

SKAN AG / Key word(s): Preliminary Results

22-Jan-2025 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

SKAN announces preliminary key figures for the 2024 financial year

Allschwil, 22 January 2025 – The SKAN Group AG, world market leader for high-quality isolator systems for aseptic production processes in the (bio-) pharmaceutical industry, expects based on preliminary, not yet audited figures net sales of around CHF 360 million (2023: CHF 320.0 million) and earnings before interest, taxes, depreciation and amortization (EBITDA) of around CHF 56 million (2023: CHF 50.1 million). Order intake is expected to reach around CHF 360 million (2023: CHF 295.1 million).

Publication of the 2024 financial results:

SKAN Group AG will publish the detailed 2024 financial results on Tuesday, March 25, 2025, at 7:00 a.m. At the same time, the 2024 Annual Report and the 2024 year-end presentation will be available for download at www.skan.com. An investor, analyst and media conference is also planned for 10:00 a.m. at the Widder Hotel in Zurich. Further details will be provided in due course.

 

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

25 March 2025 Publication Annual Results 2024
7 May 2025 Annual General Meeting 2025
19 August 2025 Publication Half-Year Results 2025

 

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs approximately 1400 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan, the USA and Brazil.


End of Inside Information


show this

MEDICLIN raises full-year guidance for the 2024 financial year

MEDICLIN AG / Key word(s): Forecast/Annual Results

MEDICLIN raises full-year guidance for the 2024 financial year

21-Jan-2025 / 16:36 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Offenburg, 21 January 2025

MEDICLIN raises full-year guidance for the 2024 financial year

MEDICLIN Aktiengesellschaft (Ticker: MED) announces that it is raising its guidance for the 2024 financial year.

Instead of a Group EBIT* between EUR 33.0 and 39.0 million, MEDICLIN now expects a Group EBIT between EUR 48.0 and 54.0 million. The sales forecast for the Group was raised from -2.0 % to 0.0 % to now 1.0 % to 3.0 %.

The preliminary figures for the fourth quarter and the 2024 financial year will be published on 27 February 2025.

* As defined on the company’s website at the following link

Contact for further information:
MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg

Ender Gülcan
Head of Investor Relations and Sustainability
Tel.: 0781/488-326
Fax: 0781/488-184
ender.guelcan@mediclin.de
www.mediclin.de
 

End of Inside Information


21-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this